dc.contributor.author | Jóźwiak, Paweł | |
dc.contributor.author | Forma, Ewa | |
dc.contributor.author | Bryś, Magdalena | |
dc.contributor.author | Krześlak, Anna | |
dc.date.accessioned | 2016-04-06T10:39:42Z | |
dc.date.available | 2016-04-06T10:39:42Z | |
dc.date.issued | 2014 | |
dc.identifier.issn | 16642392 | |
dc.identifier.uri | http://hdl.handle.net/11089/17693 | |
dc.description.abstract | Although cancer metabolism has received considerable attention over the past decade, our knowledge on its specifics is still fragmentary. Altered cellular metabolism is one of the most important hallmarks of cancer. Cancer cells exhibit aberrant glucose metabolism characterized by aerobic glycolysis, a phenomenon known as Warburg effect. Accelerated glucose uptake and glycolysis are main characteristics of cancer cells that allow them for intensive growth and proliferation. Accumulating evidence suggests that O-GlcNAc transferase (OGT), an enzyme responsible for modification of proteins with N-acetylglucosamine, may act as a nutrient sensor that links hexosamine biosynthesis pathway to oncogenic signaling and regulation of factors involved in glucose and lipid metabolism. Recent studies suggest that metabolic reprograming in cancer is connected to changes at the epigenetic level. O-GlcNAcylation seems to play an important role in the regulation of the epigenome in response to cellular metabolic status. Through histone modifications and assembly of gene transcription complexes, OGT can impact on expression of genes important for cellular metabolism. This paper reviews recent findings related to O-GlcNAc-dependent regulation of signaling pathways, transcription factors, enzymes, and epigenetic changes involved in metabolic reprograming of cancer. | pl_PL |
dc.language.iso | en | pl_PL |
dc.publisher | Frontiers | pl_PL |
dc.relation.ispartofseries | Frontiers in Endocrinology;5 | |
dc.rights | Uznanie autorstwa 3.0 Polska | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/pl/ | * |
dc.subject | O-GlcNAcylation | pl_PL |
dc.subject | cancer | pl_PL |
dc.subject | metabolism | pl_PL |
dc.subject | PI3K/Akt pathway | pl_PL |
dc.subject | transcription factors | pl_PL |
dc.subject | glycolytic enzymes | pl_PL |
dc.subject | epigenetics | pl_PL |
dc.title | O-GlcNAcylation and metabolic reprograming in cancer | pl_PL |
dc.type | Article | pl_PL |
dc.page.number | 145 | pl_PL |
dc.contributor.authorAffiliation | University of Lodz, Faculty of Biology and Environmental Protection | pl_PL |
dc.references | Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell (2012) 21:297–308. doi: 10.1016/j.ccr.2012.02.014 | pl_PL |
dc.references | Warburg O. On respiratory impairment in cancer cells. Science (1956) 124:269–70 | pl_PL |
dc.references | Warburg O. On the origin of cancer cells. Science (1956) 123:309–14. doi:10.1126/science.123.3191.309 | pl_PL |
dc.references | DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab (2008) 7:11–20. doi:10.1016/j.cmet.2007.10.002 | pl_PL |
dc.references | Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 324:1029–33. doi:10.1126/science.1160809 | pl_PL |
dc.references | Phan LM, Yeung SC, Lee MH. Cancer metabolic reprogramming: importance main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol Med (2014) 11:1–19. doi:10.7497/j.issn.2095-3941.2014.01.001 | pl_PL |
dc.references | Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A, Saavedra E. Energy metabolism in tumor cells. FEBS J (2007) 274:1393–418. doi:10.1111/j.1742-4658.2007.05686.x | pl_PL |
dc.references | Neuzil J, Moreno-Sánchez R. The bioenergetics of cancer, the Warburg hypothesis and the mitochondrial function. Curr Pharm Biotechnol (2013) 14:249–50. doi:10.2174/1389201011314030001 | pl_PL |
dc.references | Wallace DC. Mitochondria and cancer. Nat Rev Cancer (2012) 12:685–98. doi:10.1038/nrc3365 | pl_PL |
dc.references | Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol (2011) 27:441–64. doi:10.1146/annurev-cellbio-092910-154237 | pl_PL |
dc.references | Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature (2012) 491:364–73. doi:10.1038/nature11706 | pl_PL |
dc.references | Semenza GL. Regulation of metabolism by hypoxia-inducible factor 1. Cold Spring Harb Symp Quant Biol (2011) 76:347–53. doi:10.1101/sqb.2011.76.010678 | pl_PL |
dc.references | Kato Y, Lambert CA, Colige AC, Mineur P, Noël A, Frankenne F, et al. Acidic extracellular pH induces matrix metalloproteinase-9 expression in mouse metastatic melanoma cells through the phospholipase D-mitogen-activated protein kinase signaling. J Biol Chem (2005) 280:10938–44. doi:10.1074/jbc.M411313200 | pl_PL |
dc.references | Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, et al. Ketones and lactate “fuel” tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle (2010) 9:3506–14. doi:10.4161/cc.9.17.12731 | pl_PL |
dc.references | Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, et al. Ketones and lactate increase cancer cell “stemness,” driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via metabolo-genomics. Cell Cycle (2011) 10:1271–86. doi:10.4161/cc.10.8.15330 | pl_PL |
dc.references | Yeung SJ, Pan J, Lee MH. Roles of p53, Myc and HIF-1 in regulating glycolysis-the seventh hallmark of cancer. Cell Mol Life Sci (2008) 65:3981–99. doi:10.1007/s00018-008-8224-x | pl_PL |
dc.references | Soga T. Cancer metabolism: key players in metabolic reprogramming. Cancer Sci (2013) 104:275–81. doi:10.1111/cas.12085 | pl_PL |
dc.references | Wang X, Jin H. The epigenetic basis of the Warburg effect. Epigenetics (2010) 5:566–8. doi:10.4161/epi.5.7.12662 | pl_PL |
dc.references | Hanover JA, Krause MW, Love DC. The hexosamine signaling pathway: O-GlcNAc cycling in feast or famine. Biochim Biophys Acta (2010) 1800:80–95. doi:10.1016/j.bbagen.2009.07.017 | pl_PL |
dc.references | Butkinaree C, Park K, Hart GW. O-linked β-N-acetylglucosamine (O-GlcNAc): extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. Biochim Biophys Acta (2010) 1800:96–106. doi:10.1016/j.bbagen.2009.07.018 | pl_PL |
dc.references | Hart GW, Housley MP, Slawson C. Cycling of O-linked β-N-acetylglucosamine on nucleocytoplasmic proteins. Nature (2007) 446:1017–22. doi:10.1038/nature05815 | pl_PL |
dc.references | Vocadlo DJO-. GlcNAc processing enzymes: catalytic mechanisms, substrate specificity, and enzyme regulation. Curr Opin Chem Biol (2012) 16:488–97. doi:10.1016/j.cbpa.2012.10.021 | pl_PL |
dc.references | Ruan HB, Singh JP, Li MD, Wu J, Yang X. Cracking the O-GlcNAc code in metabolism. Trends Endocrinol Metab (2013) 24:301–9. doi:10.1016/j.tem.2013.02.002 | pl_PL |
dc.references | Hu P, Shimoji S, Hart GW. Site-specific interplay between O-GlcNAcylation and phosphorylation in cellular regulation. FEBS Lett (2010) 584:2526–38. doi:10.1016/j.febslet.2010.04.044 | pl_PL |
dc.references | Fardini Y, Dehennaut V, Lefebvre T, Issad T. O-GlcNAcylation: a new cancer hallmark? Front Endocrinol (2013) 4:99. doi:10.3389/fendo.2013.00099 | pl_PL |
dc.references | Ma Z, Vosseller KO-. GlcNAc in cancer biology. Amino Acids (2013) 45:719–33. doi:10.1007/s00726-013-1543-8 | pl_PL |
dc.references | de Queiroz RM, Carvalho E, Dias WBO. GlcNAcylation: the sweet side of the cancer. Front Oncol (2014) 4:132. doi:10.3389/fonc.2014.00132 | pl_PL |
dc.references | Khan KH, Yap TA, Yan L, Cunningham D. Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer (2013) 32:253–65. doi:10.5732/cjc.013.10057 | pl_PL |
dc.references | Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol (2014) 4:64. doi:10.3389/fonc.2014.00064 | pl_PL |
dc.references | Masui K, Cavenee WK, Mischel PS. mTORC2 in the center of cancer metabolic reprogramming. Trends Endocrinol Metab (2014) 25:364–73. doi:10.1016/j.tem.2014.04.002 | pl_PL |
dc.references | Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature (1995) 376:599–602. doi:10.1038/376599a0 | pl_PL |
dc.references | Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 307:1098–101. doi:10.1126/science.1106148 | pl_PL |
dc.references | Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 22:159–68. doi:10.1016/j.molcel.2006.03.029 | pl_PL |
dc.references | Hresko RC, Mueckler M. mTOR⋅ RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem (2005) 280:40406–16. doi:10.1074/jbc.M508361200 | pl_PL |
dc.references | Matheny RW, Adamo ML. Current perspectives on Akt Akt-ivation and Akt-ions. Exp Biol Med (2009) 234:1264–70. doi:10.3181/0904-MR-138 | pl_PL |
dc.references | Krzeslak A. Akt kinase: a key regulator of metabolism and progression of tumors. Postepy Hig Med Dosw (2010) 64:490–503 | pl_PL |
dc.references | Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol (2002) 4:648–57. doi:10.1038/ncb839 | pl_PL |
dc.references | Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev (2001) 15:807–26. doi:10.1101/gad.887201 | pl_PL |
dc.references | Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. Oncogene (2005) 24:6314–22. doi:10.1038/sj.onc.1208773 | pl_PL |
dc.references | Chang Y, Wang J, Lu X, Thewke DP, Mason RJ. KGF induces lipogenic genes through a PI3K and JNK/SREBP-1 pathway in H292 cells. J Lipid Res (2005) 46:2624–35. doi:10.1194/jlr.M500154-JLR200 | pl_PL |
dc.references | Vosseller K, Wells L, Lane MD, Hart GW. Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A (2002) 99:5313–8. doi:10.1073/pnas.072072399 | pl_PL |
dc.references | Buse MG, Robinson KA, Marshall BA, Hresko RC, Mueckler MM. Enhanced O-GlcNAc protein modification is associated with insulin resistance in GLUT1-overexpressing muscles. Am J Physiol Endocrinol Metab (2002) 283:E241–50. doi:10.1152/ajpendo.00060.2002 | pl_PL |
dc.references | Arias EB, Kim J, Cartee GD. Prolonged incubation in PUGNAc results in increased protein O-Linked glycosylation and insulin resistance in rat skeletal muscle. Diabetes (2004) 53:921–30. doi:10.2337/diabetes.53.4.921 | pl_PL |
dc.references | Park SY, Ryu J, Lee WO-. GlcNAc modification on IRS-1 and Akt2 by PUGNAc inhibits their phosphorylation and induces insulin resistance in rat primary adipocytes. Exp Mol Med (2005) 37:220–9. doi:10.1038/emm.2005.30 | pl_PL |
dc.references | Copeland RJ, Bullen JW, Hart GW. Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity. Am J Physiol Endocrinol Metab (2008) 295:E17–28. doi:10.1152/ajpendo.90281.2008 | pl_PL |
dc.references | Yang X, Ongusaha PP, Miles PD, Havstad JC, Zhang F, So WV, et al. Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature (2008) 451:964–9. doi:10.1038/nature06668 | pl_PL |
dc.references | Macauley MS, Bubb AK, Martinez-Fleites C, Davies GJ, Vocadlo DJ. Elevation of global O-GlcNAc levels in 3T3-L1 adipocytes by selective inhibition of O-GlcNAcase does not induce insulin resistance. J Biol Chem (2008) 283:34687–95. doi:10.1074/jbc.M804525200 | pl_PL |
dc.references | Macauley MS, Shan X, Yuzwa SA, Gloster TM, Vocadlo DJ. Elevation of global O-GlcNAc in rodents using a selective O-GlcNAcase inhibitor does not cause insulin resistance or perturb glucohomeostasis. Chem Biol (2010) 17:949–58. doi:10.1016/j.chembiol.2010.07.005 | pl_PL |
dc.references | Kang ES, Han D, Park J, Kwak TK, Oh MA, Lee SA, et al. O-GlcNAc modulation at Akt1 Ser473 correlates with apoptosis of murine pancreatic β cells. Exp Cell Res (2008) 314:2238–48. doi:10.1016/j.yexcr.2008.04.014 | pl_PL |
dc.references | McClain DA, Lubas WA, Cooksey RC, Hazel M, Parker GJ, Love DC, et al. Altered glycan-dependent signaling induces insulin resistance and hyperleptinemia. Proc Natl Acad Sci U S A (2002) 99:10695–9. doi:10.1073/pnas.152346899 | pl_PL |
dc.references | Wang S, Huang X, Sun D, Xin X, Pan Q, Peng S, et al. Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates Akt signaling. PLoS One (2012) 7:e37427. doi:10.1371/journal.pone.0037427 | pl_PL |
dc.references | Kanwal S, Fardini Y, Pagesy P, N’Tumba-Byn T, Pierre-Eugène C, Masson E, et al. O-GlcNAcylation-inducing treatments inhibit estrogen receptor α expression and confer resistance to 4-OH-tamoxifen in human breast cancer-derived MCF-7 cells. PLoS One (2013) 8:e69150. doi:10.1371/journal.pone.0069150 | pl_PL |
dc.references | Krzeslak A, Józwiak P, Lipinska A. Down-regulation of β-N-acetyl-d-glucosaminidase increases Akt1 activity in thyroid anaplastic cancer cells. Oncol Rep (2011) 26:743–9. doi:10.3892/or.2011.1333 | pl_PL |
dc.references | Onodera Y, Nam JM, Bissell MJ. Increased sugar uptake promotes oncogenesis via EPAC/RAP1 and O-GlcNAc pathways. J Clin Invest (2014) 124:367–84. doi:10.1172/JCI63146 | pl_PL |
dc.references | Jones DR, Keune WJ, Anderson KE, Stephens LR, Hawkins PT, Divecha N. The hexosamine biosynthesis pathway and O-GlcNAcylation maintain insulin-stimulated PI3K-PKB phosphorylation and tumour cell growth after short-term glucose deprivation. FEBS J (2014) 281:3591–608. doi:10.1111/febs.12879 | pl_PL |
dc.references | Park S, Pak J, Jang I, Cho JW. Inhibition of mTOR affects protein stability of OGT. Biochem Biophys Res Commun (2014). doi:10.1016/j.bbrc.2014.05.047 | pl_PL |
dc.references | Mucaj V, Shay JE, Simon MC. Effects of hypoxia and HIFs on cancer metabolism. Int J Hematol (2012) 95:464–70. doi:10.1007/s12185-012-1070-5 | pl_PL |
dc.references | Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev (2010) 20:51–6. doi:10.1016/j.gde.2009.10.009 | pl_PL |
dc.references | Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest (2013) 123:3664–71. doi:10.1172/JCI67230 | pl_PL |
dc.references | Ferrer CM, Lynch TP, Sodi VL, Falcone JN, Schwab LP, Peacock DL, et al. O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway. Mol Cell (2014) 54:820–31. doi:10.1016/j.molcel.2014.04.026 | pl_PL |
dc.references | Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer (2008) 8:976–90. doi:10.1038/nrc2231 | pl_PL |
dc.references | Albihn A, Johnsen JI, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res (2010) 107:163–224. doi:10.1016/S0065-230X(10)07006-5 | pl_PL |
dc.references | Miller DM, Thomas SD, Islam A, Muench D, Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res (2012) 18:5546–53. doi:10.1158/1078-0432.CCR-12-0977 | pl_PL |
dc.references | Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A (2008) 105:18782–7. doi:10.1073/pnas.0810199105 | pl_PL |
dc.references | Dang CV. Glutaminolysis: supplying carbon or nitrogen or both for cancer cells? Cell Cycle (2010) 9:3884–6. doi:10.4161/cc.9.19.13302 | pl_PL |
dc.references | Daye D, Wellen KE. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol (2012) 23:362–9. doi:10.1016/j.semcdb.2012.02.002 | pl_PL |
dc.references | Sears RC. The life cycle of c-myc: from synthesis to degradation. Cell Cycle (2004) 3:1133–7 | pl_PL |
dc.references | Junttila MR, Westermarck J. Mechanisms of MYC stabilization in human malignancies. Cell Cycle (2008) 7:592–6. doi:10.4161/cc.7.5.5492 | pl_PL |
dc.references | Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6:308–18. doi:10.1038/ncb1110 | pl_PL |
dc.references | Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A (2004) 101:9085–90. doi:10.1073/pnas.0402770101 | pl_PL |
dc.references | Chou TY, Dang CV, Hart GW. Glycosylation of the c-Myc transactivation domain. Proc Natl Acad Sci U S A (1995) 92:4417–21. doi:10.1073/pnas.92.10.4417 | pl_PL |
dc.references | Chou TY, Hart GW, Dang CV. c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J Biol Chem (1995) 270:18961–5. doi:10.1074/jbc.270.32.18961 | pl_PL |
dc.references | Chou TY, Hart GW. O-linked N-acetylglucosamine and cancer: messages from the glycosylation of c-Myc. Adv Exp Med Biol (2001) 491:413–8. doi:10.1007/978-1-4615-1267-7_26 | pl_PL |
dc.references | Dehennaut V, Slomianny MC, Page A, Vercoutter-Edouart AS, Jessus C, Michalski JC, et al. Identification of structural and functional O-linked N-acetylglucosamine-bearing proteins in Xenopus laevis oocyte. Mol Cell Proteomics (2008) 7:2229–45. doi:10.1074/mcp.M700494-MCP200 | pl_PL |
dc.references | Itkonen HM, Minner S, Guldvik IJ, Sandmann MJ, Tsourlakis MC, Berge V, et al. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer Res (2013) 73:5277–87. doi:10.1158/0008-5472 | pl_PL |
dc.references | Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer (2013) 12:86. doi:10.1186/1476-4598-12-86 | pl_PL |
dc.references | Napetschnig J, Wu H. Molecular basis of NF-κB signaling. Annu Rev Biophys (2013) 42:443–68. doi:10.1146/annurev-biophys-083012-130338 | pl_PL |
dc.references | Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 regulates glucose metabolism through an IKK-NF-B pathway and inhibits cell transformation. Nat Cell Biol (2008) 10:611–8. doi:10.1038/ncb1724 | pl_PL |
dc.references | Marelli-Berg FM, Fu H, Mauro C. Molecular mechanisms of metabolic reprogramming in proliferating cells: implications for T-cell-mediated immunity. Immunology (2012) 136:363–9. doi:10.1111/j.1365-2567.2012.03583.x | pl_PL |
dc.references | Mauro C, Leow SC, Anso E, Rocha S, Thotakura AK, Tornatore L, et al. NF-kB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nat Cell Biol (2011) 13:1272–9. doi:10.1038/ncb2324 | pl_PL |
dc.references | Kumar S, Donti TR, Agnihotri N, Mehta K. Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways. Int J Cancer (2014) 134:2798–807. doi:10.1002/ijc.28623 | pl_PL |
dc.references | Golks A, Tran TT, Goetschy JF, Guerini D. Requirement for O-linked N-acetylglucosaminyl transferase in lymphocytes activation. EMBO J (2007) 26:4368–79. doi:10.1016/j.febslet.2008.08.010 | pl_PL |
dc.references | Yang WH, Park SY, Nam HW, Kim H, Kang JG, Kang ES, et al. NFkappaB activation is associated with its O-GlcNAcylation state under hyperglycemic conditions. Proc Natl Acad Sci U S A (2008) 105:17345–50. doi:10.1073/pnas.0806198105 | pl_PL |
dc.references | Allison DF, Wamsley JJ, Kumar M, Li D, Gray LG, Hart GW, et al. Modification of RelA by O-linked N-acetylglucosamine links glucose metabolism to NF-κB acetylation and transcription. Proc Natl Acad Sci U S A (2012) 109:16888–93. doi:10.1073/pnas.1208468109 | pl_PL |
dc.references | Ma Z, Vocadlo DJ, Vosseller K. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells. J Biol Chem (2013) 288:15121–30. doi:10.1074/jbc.M113.470047 | pl_PL |
dc.references | Ramakrishnan P, Clark PM, Mason DE, Peters EC, Hsieh-Wilson LC, Baltimore D. Activation of the transcriptional function of the NF-κB protein c-Rel by O-GlcNAc glycosylation. Sci Signal (2013) 6:75. doi:10.1126/scisignal.2004097 | pl_PL |
dc.references | Kawauchi K, Araki K, Tobiume K, Tanaka N. Loss of p53 enhances catalytic activity of IKKbeta through O-linked beta-N-acetyl glucosamine modification. Proc Natl Acad Sci U S A (2009) 106:3431–6. doi:10.1073/pnas.0813210106 | pl_PL |
dc.references | Yamashita H, Takenoshita M, Sakurai M, Bruick RK, Henzel WJ, Shillinglaw W, et al. A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc Natl Acad Sci U S A (2001) 98:9116–21. doi:10.1073/pnas.161284298 | pl_PL |
dc.references | Wang H, Wollheim CB. ChREBP rather than USF2 regulates glucose stimulation of endogenous l-pyruvate kinase expression in insulin-secreting cells. J Biol Chem (2002) 277:32746–52. doi:10.1074/jbc.M201635200 | pl_PL |
dc.references | da Silva Xavier G, Rutter GA, Diraison F, Andreolas C, Leclerc I. ChREBP binding to fatty acid synthase and L-type pyruvate kinase genes is stimulated by glucose in pancreatic beta-cells. J Lipid Res (2006) 47:2482–91. doi:10.1194/jlr.M600289-JLR200 | pl_PL |
dc.references | Dentin R, Pégorier JP, Benhamed F, Foufelle F, Ferré P, Fauveau V, et al. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem (2004) 279:20314–26. doi:10.1074/jbc.M312475200 | pl_PL |
dc.references | Ishii S, Iizuka K, Miller BC, Uyeda K. Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc Natl Acad Sci U S A (2004) 101:15597–602. doi:10.1073/pnas.0405238101 | pl_PL |
dc.references | Iizuka K, Bruick RK, Liang G, Horton JD, Uyeda K. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci U S A (2004) 101:7281–6. doi:10.1073/pnas.0401516101 | pl_PL |
dc.references | Havula E, Hietakangas V. Glucose sensing by ChREBP/MondoA-Mlx transcription factors. Semin Cell Dev Biol (2012) 23:640–7. doi:10.1016/j.semcdb.2012.02.007 | pl_PL |
dc.references | Tong X, Zhao F, Mancuso A, Gruber JJ, Thompson CB. The glucose-responsive transcription factor ChREBP contributes to glucose-dependent anabolic synthesis and cell proliferation. Proc Natl Acad Sci U S A (2009) 106:21660–5. doi:10.1073/pnas.0911316106 | pl_PL |
dc.references | Sakiyama H, Fujiwara N, Noguchi T, Eguchi H, Yoshihara D, Uyeda K, et al. The role of O-linked GlcNAc modification on the glucose response of ChREBP. Biochem Biophys Res Commun (2010) 402:784–9. doi:10.1016/j.bbrc.2010.10.113 | pl_PL |
dc.references | Guinez C, Filhoulaud G, Rayah-Benhamed F, Marmier S, Dubuquoy C, Dentin R, et al. O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver. Diabetes (2011) 60:1399–413. doi:10.2337/db10-0452 | pl_PL |
dc.references | Ido-Kitamura Y, Sasaki T, Kobayashi M, Kim HJ, Lee YS, Kikuchi O, et al. Hepatic FoxO1 integrates glucose utilization and lipid synthesis through regulation of Chrebp O-glycosylation. PLoS One (2012) 7:e47231. doi:10.1371/journal.pone.0047231 | pl_PL |
dc.references | Clark PM, Dweck JF, Mason DE, Hart CR, Buck SB, Peters EC, et al. Direct in-gel fluorescence detection and cellular imaging of O-GlcNAc-modified proteins. J Am Chem Soc (2008) 130:11576–11571. doi:10.1021/ja8030467 | pl_PL |
dc.references | Yi W, Clark PM, Mason DE, Keenan MC, Hill C, Goddard WA, et al. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science (2012) 337:975–801. doi:10.1126/science.1222278 | pl_PL |
dc.references | Champattanachai V, Netsirisawan P, Chaiyawat P, Phueaouan T, Charoenwattanasatien R, Chokchaichamnankit D, et al. Proteomic analysis and abrogated expression of O-GlcNAcylated proteins associated with primary breast cancer. Proteomics (2013) 13:2088–991. doi:10.1002/pmic.201200126 | pl_PL |
dc.references | Noguchi T, Yamada K, Inoue H, Matsuda T, Tanaka T. The L-and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters. J Biol Chem (1987) 262:14366–71. | pl_PL |
dc.references | Noguchi T, Inoue H, Tanaka T. The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J Biol Chem (1986) 261:13807–12 | pl_PL |
dc.references | Tamada M, Suematsu M, Saya H. Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells. Clin Cancer Res (2012) 18:5554–61. doi:10.1158/1078-0432.CCR-12-0859 | pl_PL |
dc.references | Wong N, Ojo D, Yan J, Tang D. PKM2 contributes to cancer metabolism. Cancer Lett (2014). doi:10.1016/j.canlet.2014.01.031 | pl_PL |
dc.references | Kaelin WG Jr, McKnight SL. Influence of metabolism on epigenetics and disease. Cell (2013) 153:56–69. doi:10.1016/j.cell.2013.03.004 | pl_PL |
dc.references | Lu C, Thompson CB. Metabolic regulation of epigenetics. Cell Metab (2012) 16:9–17. doi:10.1016/j.cmet.2012.06.001 | pl_PL |
dc.references | Gao Z, Xu CW. Glucose metabolism induces mono-ubiquitination of histone H2B in mammalian cells. Biochem Biophys Res Commun (2011) 404:428–33. doi:10.1016/j.bbrc.2010.11.138 | pl_PL |
dc.references | Urasaki Y, Heath L, Xu CW. Coupling of glucose deprivation with impaired histone H2B monoubiquitination in tumors. PLoS One (2012) 7:e36775. doi:10.1371/journal.pone.0036775 | pl_PL |
dc.references | Espinosa JM. Histone H2B ubiquitination: the cancer connection. Genes Dev (2008) 22:2743–9. doi:10.1101/gad.1732108 | pl_PL |
dc.references | Johnsen SA. The enigmatic role of H2Bub1 in cancer. FEBS Lett (2012) 586:1592–601. doi:10.1016/j.febslet.2012.04.002 | pl_PL |
dc.references | Kim J, Hake SB, Roeder RG. The human homolog of yeast BRE1 functions as a transcriptional coactivator through direct activator interactions. Mol Cell (2005) 20:759–70. doi:10.1016/j.molcel.2005.11.012 | pl_PL |
dc.references | Zhu B, Zheng Y, Pham AD, Mandal SS, Erdjument-Bromage H, Tempst P, et al. Monoubiquitination of human histone H2B: the factors involved and their roles in HOX gene regulation. Mol Cell (2005) 20:601–11. doi:10.1016/j.molcel.2005.09.025 | pl_PL |
dc.references | Shema E, Tirosh I, Aylon Y, Huang J, Ye C, Moskovits N, et al. The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression. Genes Dev (2008) 22:2664–76. doi:10.1101/gad.1703008 | pl_PL |
dc.references | Zhang XY, Varthi M, Sykes SM, Phillips C, Warzecha C, Zhu W, et al. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell (2008) 29:102–11. doi:10.1016/j.molcel.2007.12.015 | pl_PL |
dc.references | Jääskeläinen T, Makkonen H, Visakorpi T, Kim J, Roeder RG, Palvimo JJ. Histone H2B ubiquitin ligases RNF20 and RNF40 in androgen signaling and prostate cancer cell growth. Mol Cell Endocrinol (2012) 350:87–98. doi:10.1016/j.mce.2011.11.025 | pl_PL |
dc.references | Blank M, Tang Y, Yamashita M, Burkett SS, Cheng SY, Zhang YE. A tumor suppressor function of Smurf2 associated with controlling chromatin landscape and genome stability through RNF20. Nat Med (2012) 18:227–34. doi:10.1038/nm.2596 | pl_PL |
dc.references | Liu Z, Oh SM, Okada M, Liu X, Cheng D, Peng J, et al. Human BRE1 is an E3 ubiquitin ligase for Ebp1 tumor suppressor. Mol Biol Cell (2009) 20:757–68. doi:10.1091/mbc.E08-09-0983 | pl_PL |
dc.references | Sakabe K, Wang Z, Hart GW. β-N-acetylglucosamine (O-GlcNAc) is part of the histone code. Proc Natl Acad Sci U S A (2010) 107:19915–20. doi:10.1073/pnas.1009023107 | pl_PL |
dc.references | Fujiki R, Hashiba W, Sekine H, Yokoyama A, Chikanishi T, Ito S, et al. GlcNAcylation of histone H2B facilitates its monoubiquitination. Nature (2011) 480:557–60. doi:10.1038/nature10656 | pl_PL |
dc.references | Chen Q, Chen Y, Bian C, Fujiki R, Yu X. TET2 promotes histone O-GlcNAcylation during gene transcription. Nature (2013) 493:561–4. doi:10.1038/nature11742 | pl_PL |
dc.references | Deplus R, Delatte B, Schwinn MK, Defrance M, Mendez J, Murphy N, et al. TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO J (2013) 32:645–55. doi:10.1038/emboj.2012.357 | pl_PL |
dc.references | Xu Q, Yang C, Du Y, Chen Y, Liu H, Deng M, et al. AMPK regulates histone H2B O-GlcNAcylation. Nucleic Acids Res (2014) 42:5594–604. doi:10.1093/nar/gku236 | pl_PL |
dc.references | Chu CS, Lo PW, Yeh YH, Hsu PH, Peng SH, Teng YC, et al. O-GlcNAcylation regulates EZH2 protein stability and function. Proc Natl Acad Sci U S A (2014) 111:1355–60. doi:10.1073/pnas.1323226111 | pl_PL |
dc.references | Benetatos L, Vartholomatos G, Hatzimichael E. Polycomb group proteins and MYC: the cancer connection. Cell Mol Life Sci (2014) 71:257–69. doi:10.1007/s00018-013-1426-x | pl_PL |
dc.references | Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu H, et al. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol (2007) 27:5105–19. doi:10.1128/MCB.00162-07 | pl_PL |
dc.references | Liu X, Wang X, Zhang J, Lam EK, Shin VY, Cheng AS, et al. Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene (2010) 29:442–50. doi:10.1038/onc.2009.332 | pl_PL |
dc.references | Ashburner BP, Westerheide SD, Baldwin AS Jr. The p65 (RelA) subunit of NFkappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol (2001) 21:7065–77. doi:10.1128/MCB.21.20.7065-7077.2001 | pl_PL |
dc.references | Bhat KP, Pelloski CE, Zhang Y, Kim SH, deLaCruz C, Rehli M, et al. Selective repression of YKL-40 by NFkappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2. FEBS Lett (2008) 582:3193–200. doi:10.1016/j.febslet.2008.08.010 | pl_PL |
dc.references | Yang X, Zhang F, Kudlow JE. Recruitment of O-GlcNAc transferase to promoters by corepressor mSin3A: coupling protein O-GlcNAcylation to transcriptional repression. Cell (2002) 110:69–80. doi:10.1083/jcb.200206015 | pl_PL |
dc.contributor.authorEmail | krzeslak@biol.uni.lodz.pl | pl_PL |
dc.identifier.doi | 10.3389/fendo.2014.00145 | |